Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Syro, Luis V., Rotondo, Fabio, Camargo, Mauricio, Ortiz, Leon D., Serna, Carlos A., Kovacs, Kalman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013558/
https://www.ncbi.nlm.nih.gov/pubmed/29963012
http://dx.doi.org/10.3389/fendo.2018.00318
_version_ 1783334038836084736
author Syro, Luis V.
Rotondo, Fabio
Camargo, Mauricio
Ortiz, Leon D.
Serna, Carlos A.
Kovacs, Kalman
author_facet Syro, Luis V.
Rotondo, Fabio
Camargo, Mauricio
Ortiz, Leon D.
Serna, Carlos A.
Kovacs, Kalman
author_sort Syro, Luis V.
collection PubMed
description Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.
format Online
Article
Text
id pubmed-6013558
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60135582018-06-29 Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions Syro, Luis V. Rotondo, Fabio Camargo, Mauricio Ortiz, Leon D. Serna, Carlos A. Kovacs, Kalman Front Endocrinol (Lausanne) Endocrinology Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Frontiers Media S.A. 2018-06-15 /pmc/articles/PMC6013558/ /pubmed/29963012 http://dx.doi.org/10.3389/fendo.2018.00318 Text en Copyright © 2018 Syro, Rotondo, Camargo, Ortiz, Serna and Kovacs. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Syro, Luis V.
Rotondo, Fabio
Camargo, Mauricio
Ortiz, Leon D.
Serna, Carlos A.
Kovacs, Kalman
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
title Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
title_full Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
title_fullStr Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
title_full_unstemmed Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
title_short Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
title_sort temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013558/
https://www.ncbi.nlm.nih.gov/pubmed/29963012
http://dx.doi.org/10.3389/fendo.2018.00318
work_keys_str_mv AT syroluisv temozolomideandpituitarytumorscurrentunderstandingunresolvedissuesandfuturedirections
AT rotondofabio temozolomideandpituitarytumorscurrentunderstandingunresolvedissuesandfuturedirections
AT camargomauricio temozolomideandpituitarytumorscurrentunderstandingunresolvedissuesandfuturedirections
AT ortizleond temozolomideandpituitarytumorscurrentunderstandingunresolvedissuesandfuturedirections
AT sernacarlosa temozolomideandpituitarytumorscurrentunderstandingunresolvedissuesandfuturedirections
AT kovacskalman temozolomideandpituitarytumorscurrentunderstandingunresolvedissuesandfuturedirections

Ejemplares similares